Literature DB >> 17481659

Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites.

David J King1, Jiri G Safar, Giuseppe Legname, Stanley B Prusiner.   

Abstract

Binding of nucleic acids to the prion protein (PrP) created a conundrum that required distinguishing between non-specific interactions and biologically important polynucleotides. In the process of developing selective ligands for PrP, we found using a single-stranded DNA thioaptamer library that the binding of thioaptamers to PrP occurs on at least two different sites on the protein. Selection against recombinant (rec) PrP of Syrian hamster (SHa) sequence 90-231 folded into an alpha-helical-rich conformation identified a 12-base consensus sequence within a series of 20 thioaptamers, all of which consist of 40 bases. Each thioaptamer was comprised of both normal and thio-dA modified bases. One thioaptamer designated 97 bound to recSHaPrP with affinity of 0.58(+/-0.1) nM; lower affinities for bovine (Bo), and human (Hu) were found, establishing that binding is dependent on the primary structure of PrP. High affinity binding of thioaptamer 97 to PrP was found to be mediated through the dodecyl sequence GACACAAGCCGA within the consensus region with five critical backbone modifications 5' to each dA residue. A control oligonucleotide with an equivalent number of phosphorothioates to thioaptamer 97 and a scrambled consensus sequence could not distinguish among the three PrP sequences. Control oligonucleotides bearing non-selected sequences bound to PrP at a sequence-independent DNA-binding site. In contrast, the high-affinity binding of thioaptamer 97 to PrP depends on (1) backbone modifications, (2) oligonucleotide sequence, and (3) PrP sequence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17481659     DOI: 10.1016/j.jmb.2007.02.004

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  25 in total

Review 1.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

2.  Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Authors:  Farid Rahimi; Gal Bitan
Journal:  J Vis Exp       Date:  2010-05-13       Impact factor: 1.355

Review 3.  Tumor-targeted drug delivery with aptamers.

Authors:  Y Zhang; H Hong; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.

Authors:  Marcela V Karpuj; Kurt Giles; Sagit Gelibter-Niv; Michael R Scott; Vishwanath R Lingappa; Francis C Szoka; David Peretz; Wilfred Denetclaw; Stanley B Prusiner
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

6.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

Review 7.  Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases.

Authors:  Yraima Cordeiro; Bruno Macedo; Jerson L Silva; Mariana P B Gomes
Journal:  Biophys Rev       Date:  2014-01-09

Review 8.  Aptamers and the next generation of diagnostic reagents.

Authors:  Varatharasa Thiviyanathan; David G Gorenstein
Journal:  Proteomics Clin Appl       Date:  2012-12       Impact factor: 3.494

9.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

Review 10.  Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.

Authors:  Jerson L Silva; Tuane C R G Vieira; Mariana P B Gomes; Ana Paula Ano Bom; Luis Mauricio T R Lima; Monica S Freitas; Daniella Ishimaru; Yraima Cordeiro; Debora Foguel
Journal:  Acc Chem Res       Date:  2010-02-16       Impact factor: 22.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.